A large review of 37 weight-loss studies found that people who rely solely on GLP-1 therapy tend to regain weight more quickly once treatment stops compared with those who also adopt behavioral changes
GLP-1s are the most significant investment-grade human-capital opportunity currently available
Thats where DISONCARE products come in
It belongs to a broader group of injectable medications commonly discussed alongside Ozempic and Mounjaro in current GLP-1 litigation and weight loss drug safety discussions
Because GLP-1s are intended to be used alongside lifestyle changes, pairing medication with nutrition, behavior change, and metabolic health support may help employers maximize the value of these medications
Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G., and Guarnieri, G